Fadi Khasawneh, PhD, B.Pharm
Assistant Professor of Pharmaceutical Sciences
College of Pharmacy
Phone: 909-706-3738 |
2007 University of Illinois at Chicago
1999 Jordan University of Science and Technology
My research is focused on the study of thrombosis and platelet biology. One of our goals is to delineate signaling pathways involved in human/mouse platelet activation (e.g., aggregation, shape change, and secretion), and to investigate their role in the pathogenesis of thrombotic diseases. Another goal is to map the G-protein coupling domains of certain platelet G-protein coupled receptors. We will employ a host of molecular, biochemical and pharmacological approaches, as well as an in vivo Carotid Artery Thrombosis model in our studies. Our ultimate goal is to identify novel therapeutic targets for the management of thromboembolic disorders.
Khasawneh, F.T., Huang, J., Turek, J., and Le Breton, G.C., “Differential Mapping of the Amino Acids Mediating Agonist and Antagonist Coordination with the Human Thromboxane A2 Receptor Protein,” J. Biol. Chem., Vol. 281 (37), 26951-26965, 2006.
Khasawneh, F.T., Huang, J., Mir, F., Srinivasan, S., Tiruppathi, C., and Le Breton, G.C., “Characterization of Isoprostane Signaling: Evidence for a Unique Coordination Profile of 8-iso-PGF2α with the Thromboxane A2 Receptor, and Activation of a Separate cAMP-Dependent Inhibitory Pathway in Human Platelets,” Biochemical Pharmacology, Vol. 75, 2301-2315, 2008.
Srinivasan, S., Mir, F., Huang, J., Khasawneh, F.T., Lam, S.C., and Le Breton, G.C.,“The P2Y12 Antagonists, 2-Methylthioadenosine 5’-Monophosphate Triethylammonium Salt and Cangrelor (ARC69931MX), Can Inhibit Human Platelet Aggregation through a Gi-independent Increase in cAMP Levels,” J. Biol. Chem., Vol. 284 (24), 16108-16117, 2009.
Ting, H.J, and Khasawneh, F.T., “Platelet Function and Isoprostane Biology. Should Isoprostanes Be the Newest Member of the Orphan-Ligand Family?”Journal of Biomedical Science2010, 17:24
Ting H.J., andKhasawneh, F.T.,“Glybenclamide: an antidiabetic with in vivo antithrombotic activity”. Eur. J. Pharmacol, 649, 249–254, 2010.